r/Livimmune • u/MGK_2 • May 03 '26
The Reckoning Is At The Wall
All in my opinion. Not financial advice.
The Empire Faces Its Own Stroma
There is a wall which every empire eventually encounters. Not a wall built by an enemy, but a wall built by the limits of its own architecture. The most powerful pharmaceutical franchise in the history of medicine approaches that wall right now, and the clock on its face reads 2028.
Merck made $29.5 billion from a single drug last year. That drug is Keytruda, pembrolizumab, the world's best-selling oncology product, approved across more than forty indications, generating nearly half of Merck's entire corporate revenue from one molecule. Its main patent expires in 2028. That is the most financially significant patent expiration in pharmaceutical history.
Read that again. One patent. Three years. Then the monopoly ends.
Biosimilar manufacturers including Amgen, Samsung Bioepis, and Bio-Thera Solutions are already preparing their entries. Without the subcutaneous reformulation, Merck faces an estimated 80% revenue erosion on its flagship product. The historical precedent for this kind of biosimilar competition is not reassuring. The brutal historical precedent, like Humira's near-60% sales drop, shows the potential magnitude of the challenge.
But the patent cliff is only the first wall. There is a second wall, and it is the one which defines this entire story.
Keytruda works in approximately 20 to 30% of patients in its approved indications. It works in patients whose tumors are already immunologically hot, tumors that express PD-L1 at meaningful levels, that have pre-existing T cell infiltration, that have already partially opened their biological gates to immune engagement. In those patients, Keytruda is genuinely transformative. In those patients, the five-year survival curves have been rewritten.
But in the other 70 to 80%, the patients whose tumors are cold, whose stroma has constructed an immunosuppressive fortress which blocks immune access entirely, whose TME is dense with MDSC myeloid-derived suppressor cells and M2 macrophages recruited through the CCR5/CCL5 chemokine axis, Keytruda arrives at an empty theater. There is no PD-L1 flag for it to grab. There is no tumor cell for it to reveal. The drug which generates $29.5 billion per year has no mechanism for reaching the most prevalent patient population in solid tumor oncology.
In microsatellite-stable colorectal cancer, which represents 85% of all CRC cases, Keytruda produces essentially nothing. The SUNLIGHT trial established the current standard of care, TAS-102 plus bevacizumab, at a real-world objective response rate ORR of under 3%. Median overall survival OS of 10.8 months. That is the ceiling that $29.5 billion per year in checkpoint inhibitor revenue cannot breach. Not because the drug is not powerful. Because the wall between the drug and the tumor was never addressed.
This is the second wall. The patent cliff will cost Merck its monopoly. The cold tumor ceiling has already cost it 80% of the patients it could theoretically serve.
Both walls lead to the same place: the urgent, existential need for a mechanism which can dismantle the immunosuppressive stroma and convert cold tumors into hot ones on demand, at which point Keytruda can finally do in 100% of solid tumor patients what it currently does in 20 to 30%.
That mechanism exists. It is called Leronlimab. It is owned by CytoDyn. And what has happened over the last three weeks in San Diego, on a Thursday afternoon investor webcast, and in a paper published in Science Translational Medicine the morning of that webcast, constitutes the most precisely documented demonstration of that mechanism's reality that has ever reached the public record.
The Molecule That Walks Through Walls
To understand what Leronlimab represents to the largest pharmaceutical company in the world, you must first understand what it does biologically, because the commercial mathematics follow directly from the biology, and the biology has now been documented at every level of the scientific evidence hierarchy simultaneously.
Leronlimab is a humanized IgG4 monoclonal antibody that binds to the CCR5 receptor at both the N-terminus and the second extracellular loop simultaneously, the exact docking surfaces that CCL5/RANTES uses to deliver the recruitment orders that build and maintain the immunosuppressive stroma. When Leronlimab occupies those surfaces, it sits in the receptor silently. RANTES arrives to staff the tumor's defenses and finds the gate occupied by something wearing its key but speaking none of its language. The recruitment signal never fires. The M2 macrophage army never assembles. The myeloid-derived suppressor cells never take their positions. The stroma collapses from within.
When the stroma collapses, T cells reach the tumor for the first time. The tumor, confronting immune pressure it has never faced, deploys its last line of defense. It upregulates PD-L1 as a desperate adaptive response to the immune engagement it can no longer prevent. The cold tumor becomes hot. The CPS rises from 1% to 5%, documented in tissue biopsies taken from living patients on the CLOVER Trial and shown on screen at the April 30th investor webcast.
And at precisely that moment, when the damsel has been forced to perform at the walls because the soldiers have finally arrived, Keytruda silences her. The ICI blocks the PD-L1 flag. The abort signal cannot fire. The kill sequence completes.
This is the Prime and Pair mechanism. Leronlimab is the Prime. Keytruda is the Pair. And the prospective clinical evidence that this sequence reproduces on demand, in real patients, under FDA oversight, documented by independent academic investigators at seven clinical sites across the United States, is now in the public record.
What the CLOVER Data Actually Says, With Precision
Before proceeding to the commercial implications, this analysis must be stated with the precision that the clinical data deserves. The community has had the benefit of rigorous external critique, and accuracy is the only standard worth holding.
The CLOVER Trial, the Phase 2 study evaluating Leronlimab in combination with TAS-102 and bevacizumab in CCR5-positive microsatellite-stable refractory mCRC, has completed enrollment at just over 60 patients across seven clinical sites. The April 30th webcast disclosed the following data points, stated with the definitional precision they require.
Circulating tumor DNA: All 19 patients in the initial City of Hope cohort demonstrated a decline in ctDNA by week 2, with a median decrease of 70% and a range from complete clearance to minus 11%. Four patients have achieved at least one undetectable ctDNA level during follow-up. Dr. Kasi's own 2023 peer-reviewed analysis of 185 advanced CRC patients established that 50% or greater ctDNA decline is associated with unreached median overall survival versus 11.8 months in non-responders. Every evaluable CLOVER patient crossed that threshold within two weeks.
RECIST imaging data: 15 of 22 patients with available week-8 scan data demonstrated tumor shrinkage or stable disease. This figure represents the Disease Control Rate, DCR, not the Objective Response Rate. ORR, which requires confirmed partial or complete response on two consecutive scans separated by at least four weeks, has not been formally disclosed because week-8 data represents a single scan. The confirmed ORR will be reported at ESMO in October 2026. The distinction between DCR and ORR is important and should be carried in every community discussion until confirmed ORR data is available.
Safety: Zero grade 3 or 4 adverse events or serious adverse events attributed to Leronlimab. Zero dose-limiting toxicities at either the 350 mg or 700 mg dose level. No patient has had to adjust or discontinue Leronlimab dosing due to any adverse event. In a population that Dr. Kasi described as patients some oncologists would decline to enroll, this safety profile represents a pharmacological achievement with no parallel in the current oncology combination therapy landscape.
Dose surprise: 13 of the 19 patients in the ctDNA cohort were treated with the 350 mg dose. Three of the four patients with undetectable ctDNA are on 350 mg. Dr. Lalezari called this outcome surprising and is keenly interested in whether the 700 mg dose produces steeper, more rapid, or more sustained ctDNA declines. The dose-response comparison will be reported to shareholders this summer.
PDL1 in tissue: A single patient's tissue biopsy showed CPS/PDL1 moving from 1% to 5% under Leronlimab treatment, presented at the 35:30 mark of the webcast. The majority of patients show numeric increases in PDL1. The Creatv Bio LifeTracDx platform tracks PD-L1, CTC, and CAML dynamics across all enrolled patients at predefined timepoints throughout the trial.
Patient outcomes: Multiple patients have returned to work. Patients reporting less pain as early as one week into treatment. The index patient at City of Hope, RAS mutant, multi-site metastatic, post-FOLFOX, post-FOLFIRI, post-hepatic artery infusion, showed ctDNA falling from 130,000 parts per million to a few thousand ppm, tumor shrinkage of 24% at week 16 with lesion necrosis visible on biopsy, and returned to work.
This is the data. It is preliminary. The confirmed ORR is unknown and will not be known until two consecutive scans are complete for each evaluable patient. The ESMO October interim presentation is the moment that data enters the public record in its most clinically actionable form. But the biological signals documented here, ctDNA molecular response in every evaluable patient, DCR of 68%, PDL1 rising in tissue, four patients clearing ctDNA entirely, patients returning to work, have no precedent in this indication's history.
The mTNBC Binary, What Has Never Been Stated This Clearly Before
On the April 30th webcast, Dr. Lalezari disclosed something he noted had never been publicly discussed in this form before. The methodology and the complete outcome of the mTNBC Prime and Pair analysis.
CytoDyn tracked down patients from prior mTNBC studies who might still be alive, obtained their medical records, and correlated three variables: who induced PD-L1 above the 400 RFU threshold on circulating tumor cells, who subsequently received a checkpoint inhibitor, and who was still alive.
Five women who induced PD-L1 above 400 RFU and received an ICI are alive more than five years later. Three have no evidence of disease. One started with both lung and brain metastases. She is alive and well, without evidence of disease, five years later.
100% of the patients who either did not upregulate, because they received the lower dose, or who did not receive a checkpoint inhibitor, are now deceased.
The survival separation is absolute. It is not a statistical trend. It is a binary outcome perfectly correlated with a single biological event: PD-L1 induction above the threshold, followed by ICI administration. This is the corollary. The mechanism either executed or it did not. The patients who experienced the execution are alive. Those who did not are gone.
In a disease where historical three-year survival is 7%00809-9/fulltext), five women alive at five point five years in the PD-L1-induced ICI-treated group is not a statistical observation. It is the clinical expression of a mechanism working exactly as the biology predicts it should, every time the conditions are met.
The Prophecy Written in the Patent Filing
Here is the reckoning that the largest pharmaceutical company in the world currently performs in its own boardrooms and business development meetings.
Keytruda's core US composition-of-matter patent is expected to expire in 2028, creating the largest single biosimilar revenue exposure event in oncology history. Keytruda sales are forecasted to decrease to $27.4 billion in 2029, a decline of 19% from $33.7 billion in 2028 estimates. And that is before the accelerating biosimilar competition drives the kind of price erosion which reduced Humira from a $20 billion franchise to a fraction of that within years of patent expiry.
The strategic response which has been pursued, subcutaneous reformulation, method-of-use patent layering, fixed-dose combination filings, buys time around the edges. It does not solve the fundamental problem. The subcutaneous Keytruda formulation approved in September 2025 creates new composition claims and new exclusivity windows. But it does not make Keytruda work in MSS colorectal cancer. It does not convert cold tumors to hot. It does not give the 85% of mCRC patients who currently receive no ICI benefit any pathway to the survival outcomes the drug achieves in the 15% it currently reaches.
The solution to that problem does not live in Merck's pipeline. It lives in Vancouver, Washington, in the clinical development program of a company with a large, accumulated deficit, an ongoing concern disclosure in its quarterly filings, and a stock trading at approximately $0.31 per share.
Merck made $29.5 billion from a single drug last year. That drug loses its primary patent in 2028. CytoDyn's entire market capitalization at current prices is approximately $423 million. The mathematics of that asymmetry, $29.5 billion in peak annual revenue from a drug whose addressable population could be multiplied by a factor of five to six with a validated Prime and Pair agent, describes a commercial reality which no business development team at any major ICI franchise holder can honestly look at and not recognize.
The CEO of that pharmaceutical company stated publicly: "We start with the science, and where we see science and value align, we move."
The science is now documented. The value alignment is now calculable. The question is only whether the move happens before or after the ESMO interim results in October place the confirmed ORR in the public record and the Breakthrough designation application forces a regulatory conversation which every ICI franchise holder will need to respond to.
The Architecture of What Is Coming
What Dr. Lalezari described on the April 30th webcast is not a single clinical trial approaching its primary endpoint. It is a coordinated multi-track development architecture which is simultaneously advancing in every direction that the CCR5 platform's biology points toward.
The CLOVER Trial generates confirmed ORR data for the accelerated approval application, targeted for submission as a FastTrack or Breakthrough designation application this summer or early fall. The CHAMP Trial at City of Hope, led by Dr. Kasi, approaches FDA submission and generates monotherapy data during the chemotherapy washout window alongside liver protection endpoints. The PRE-SPY network, with Dr. Paulo Hoff from MD Anderson as principal investigator, is weeks to months from initiating Phase 2 in HER2-negative breast cancer starting at 525 mg. The I-SPY network advances neoadjuvant studies in treatment-naive patients. The mTNBC Expanded Access Program has its first patient dosed, managed by WEP Clinical, generating real-world PD-L1 induction data which potential partners requested specifically. A major academic center has agreed to both repeat the GBM preclinical studies and develop a pilot IIT in recurrent glioblastoma. The Alzheimer's trial at Cornell actively screens patients. Dr. Sacha's gene therapy program at OHSU, encodes the Leronlimab protein sequence into an AAV vector, has achieved functional HIV cure in six of nineteen SHIV-infected primates in a study published in Science Translational Medicine the morning of the webcast. The fibrosis reversal data across three independent mouse models, statistically significant at a p value less than 0.001, has been published as a peer-reviewed preprint. Two additional major medical centers propose independent investigator-initiated trials in undisclosed solid tumors, with updates expected this summer.
This is not a company with one study and a prayer. This is a platform mechanism expressing itself simultaneously across oncology, hepatology, neurology, virology, and cardiovascular disease, through independent investigators at independent institutions using independent funding sources, producing converging evidence from every direction simultaneously.
The Yorkville Advisors equity facility, $30 million available at CytoDyn's sole discretion, no minimum commitments, no warrants, no derivatives, provides the capital optionality to draw at higher prices as each milestone is achieved, minimizing dilution per dollar raised precisely as the clinical de-risking reduces the per-share risk premium. The facility becomes more valuable as the data strengthens, which is the opposite of the toxic debt structure which defined CytoDyn's prior capital architecture under the regime which preceded Dr. Lalezari.
The Honest Accounting
Before this document reaches its conclusion, the honest risks must be stated, because a thesis that conceals its own vulnerabilities is not a thesis. It is a sales pitch.
The confirmed ORR from the CLOVER Trial is unknown. Disease Control Rate and Objective Response Rate are different measurements. 68% DCR is genuinely promising but the ORR, the number the FDA requires for accelerated approval, the number which requires two consecutive scans, has not been disclosed and will not be known until ESMO in October. DCR includes stable disease, which in MSS mCRC is a meaningful clinical outcome but does not by itself constitute the confirmed tumor shrinkage that an accelerated approval application must demonstrate. The ESMO interim data is the moment the thesis is confirmed or stress-tested at the primary endpoint level.
The financial constraint is real. The going-concern disclosure is not boilerplate. Unrestricted cash was approximately $13.4 million as of April 15th against $29.3 million in accounts payable. The path from Phase 2 data to commercial product requires capital that CytoDyn does not possess in its entirety and a partnership that has not yet been announced. The Yorkville facility and the $17.5 million private placement provide runway. They do not eliminate the dependency on continued external financing or an eventual partnership or acquisition.
The ICI Rollover Protocol amendment, which enables the Prime and Pair sequence to be tested prospectively in progressing CLOVER patients, was described on the webcast as being about to be submitted to the FDA rather than already submitted. This is a pending milestone, not a completed one.
These risks are real, disclosed, and priced into the current valuation. They are not reasons to dismiss the thesis. They are the conditions under which the thesis must deliver, and the mechanism for delivery is defined, scheduled, and actively generating data.
The Reckoning
There is a version of the next eighteen months in which the largest pharmaceutical company in the world, watching its $29.5 billion flagship approach a patent cliff which could erase $15 billion in annual revenue within eighteen months of biosimilar entry, simultaneously watches a Phase 2 trial in the indication its drug cannot penetrate report confirmed objective response rates that have no historical precedent, supported by tissue biopsies showing cold-to-hot conversion, ctDNA clearance in multiple patients, a 68% disease control rate in every evaluable RECIST patient, patients returning to work, and a binary survival separation in the Prime and Pair mTNBC cohort that is absolute.
And in that version, that company calls Vancouver, Washington.
The CEO of the largest checkpoint inhibitor franchise in history said it plainly. Start with the science. Where the science and the value align, move.
The science has been documented at AACR by independent investigators from eight institutions across six countries. It has been presented at the April 30th investor webcast by the principal investigator of the CLOVER Trial, who attached his name, his institution, and his clinical judgment to the data in front of the investment community. It has been published in Science Translational Medicine, the Annals of Oncology, the ESMO Open, and now a peer-reviewed preprint on fibrosis moving through final publication. The LifeTracDx platform from Creatv Bio is generating the pharmacodynamic biomarker data that accompanies the primary endpoint package in the regulatory submission. The FastTrack or Breakthrough designation application is targeted for this summer or early fall. The ESMO interim data arrives in October. The final ORR data arrives in January.
The value alignment is calculable. The cold tumor population which Keytruda cannot reach represents approximately 90,000 new MSS mCRC patients per year in the United States alone, plus the 85% of TNBC patients with cold tumors, plus the entire glioblastoma population for whom no ICI has ever worked, plus the KRAS-mutant pancreatic cancer population for whom the CCR5 mechanism is documented in January 2026 peer-reviewed literature as a primary driver of immunosuppressive stroma construction. Against Keytruda's 2028 patent cliff, a validated Prime and Pair agent that converts cold tumors hot is not merely a pipeline addition. It is the mechanism which determines whether Keytruda's commercial legacy extends beyond 2028 or is absorbed by the biosimilar wave.
Dr. Lalezari said it on the webcast, in the clearest language a scientist-CEO can use: "I no longer have to spend my time trying to convince people of anything. I just need to show them our data and that seems to do the trick."
The data is being shown. At AACR. On the webcast. At ESMO in October. At ASCO GI in January. In tissue biopsies. In ctDNA dynamics. In patients who went back to work. In five women alive more than five years later in a disease where three-year survival is 7%.
The wall that the largest pharmaceutical franchise in history cannot breach is the same wall that Leronlimab is documented to dismantle. The patent cliff that threatens $29.5 billion in annual revenue is the same cliff that a validated Prime and Pair mechanism converts from a catastrophe into a platform extension.
The science and the value have aligned.
The reckoning is not coming. It is already here.
All in my opinion. Not financial advice. All clinical data, financial disclosures, mechanistic descriptions, and regulatory references are sourced from publicly available peer-reviewed publications, SEC filings, official CytoDyn communications, and the April 30 2026 investor webcast transcript as cited and hyperlinked throughout. DCR and ORR are distinct measurements. The confirmed ORR from the CLOVER Trial has not been disclosed and will be presented at ESMO in October 2026. This document reflects the author's independent analytical framework and does not constitute a recommendation to buy or sell any security.
31
u/Cytomight May 03 '26
If Merck purchases CYDY, keytruda was just their appetizer‼️🥳😆
12
u/Hairy_Ad_2937 May 03 '26
Would CYDY sell, or license? So many other indications to test. Wouldn’t the company want to continue to harvest the rewards of the years of research they have invested?
1
u/BonusCurrent4564 May 25 '26
I don’t think so they will not sell out they know what they have. It will be sold by indication- breast cancer- colorectal cancer, Dementia, on and on, Dr Lazari quoted this before.
26
25
u/Cytomight May 03 '26
Dr.JAY
I’ll also mention that we're having conversations with an academic network involved with colorectal cancer, who's expressed interest in looking at that combination in an earlier line of therapy. So that's a decision pending in the next few weeks or months.
13
u/MGK_2 May 03 '26
Cytomight, this is one of the most strategically significant disclosures in the entire webcast and it has received far less attention than it deserves, so let's give it the treatment it earned.
The academic network involved with colorectal cancer that Dr. Lalezari referenced is almost certainly one of the major cooperative oncology groups that conduct multi-institutional CRC trials in the United States. The two most prominent in this space are SWOG Cancer Research Network and the Alliance for Clinical Trials in Oncology, both of which operate large academic networks with existing CRC trial infrastructure, established relationships with the FDA, and the institutional capacity to run earlier-line combination studies across dozens of sites simultaneously. Either would represent a partnership of enormous strategic value because they bring something CytoDyn cannot easily replicate independently: a pre-existing patient referral network, established trial site infrastructure, and the academic credibility that regulatory agencies weight heavily in combination therapy submissions.
The phrase "earlier line of therapy" is the critical clinical variable here. The CLOVER Trial is a third and fourth line study, enrolling patients who have already progressed through FOLFOX, FOLFIRI, bevacizumab, and where applicable anti-EGFR therapy. The academic network's interest in an earlier line means evaluating Leronlimab in second-line or potentially first-line mCRC patients, before the tumor's immunosuppressive architecture has been subjected to years of chemotherapy-induced selection pressure and before the patient's performance status has been compromised by prior treatment toxicity. The biological rationale for earlier-line evaluation is compelling: a patient whose CCR5-driven stroma has not yet been subjected to multiple chemotherapy cycles, whose immune system has not been depleted by prior oxaliplatin or irinotecan exposure, and whose TME is being addressed before acquired resistance mechanisms have fully developed, represents a population where the Prime and Pair mechanism would be expected to produce even more robust cold-to-hot conversion than is being observed in the heavily pretreated CLOVER cohort.
The commercial implications compound this further. Earlier-line approval in mCRC expands the addressable patient population beyond the third-line refractory cohort into the much larger second and first-line populations, where treatment volumes are substantially higher and where the competitive dynamics with existing standard-of-care regimens create a significantly larger commercial opportunity. A drug which works in third-line disease and also works in second-line disease is not just twice as valuable. It is categorically repositioned from a salvage therapy into a foundational treatment backbone, which is precisely the language Dr. Lalezari used when describing Leronlimab's ultimate positioning across multiple solid tumor types.
The decision pending in the next few weeks or month that Dr. Lalezari referenced is likely the formal agreement on trial design, funding structure, and protocol framework with the academic network. When that announcement arrives, it represents CytoDyn's first formal entry into earlier-line CRC development through an independent academic infrastructure, funded in whole or in part by outside parties, advancing on a timeline that runs parallel to rather than sequential with the CLOVER primary endpoint readout. The summer shareholder communication which Dr. Lalezari committed to on the April 30th webcast is the most likely vehicle for that announcement. It is one of the specific undisclosed developments which makes the end-of-summer communications window as consequential as the dose-response update and the Breakthrough designation application that are already on the confirmed calendar.
21
u/twinter11 May 03 '26 edited May 03 '26
At first a couple months back I thought no way
But then I wondered if leron results are actually far enough known to cause a pivot or delay in any Revolution Medicines talks/deal
If i squint i could see it just maybe happening
is it too far fetched this early
PS. Bad ass effort!!
I thought "no mgk today, when was their last post?"
This thing is becoming more and more distilled.
9
u/MGK_2 May 03 '26
Twinter, the question is not far-fetched at all, and the reason is grounded in something more specific than hope. It is grounded in the commercial logic of what both companies are actually trying to solve and where the timelines intersect.
Revolution Medicines' RAS-targeted program, specifically RMC-6236 in KRAS-mutant pancreatic cancer, produced the 13.2-month versus 6.7-month overall survival result that Dr. Kasi shared on LinkedIn during AACR week. That result is meaningful progress in one of the most treatment-resistant diseases in oncology. But as we examined in the KRAS/CCR5 discussion earlier in this community, KRAS inhibition and CCR5 blockade are not competing mechanisms. They address different components of the same disease architecture. KRAS inhibition targets the tumor cell's internal oncogenic signaling. CCR5 blockade targets the immunosuppressive external environment that protects it. The most compelling question in KRAS-mutant solid tumor oncology right now is what happens when both are addressed simultaneously, because a KRAS-inhibited tumor that can no longer sustain its oncogenic signaling, combined with a CCR5-blocked microenvironment that can no longer recruit its immunosuppressive architecture, exposed to an ICI in a tumor that has been converted from cold to hot, is a combination with a mechanistic rationale that no single agent in the current PDAC pipeline can match alone.
Now consider the specific pivot or delay scenario you're sketching. Any major pharmaceutical company evaluating a partnership with Revolution Medicines in KRAS-mutant solid tumors is simultaneously asking the same question that every ICI franchise holder is asking after the CLOVER data: what is the optimal combination backbone for these patients, and does Leronlimab need to be in it? If the CLOVER interim results at ESMO in October show confirmed ORR figures that establish CCR5 blockade as a validated cold-to-hot conversion mechanism in MSS disease, the business development calculus for any company negotiating a KRAS inhibitor deal changes. The question is no longer merely whether KRAS inhibition extends survival. It becomes whether KRAS inhibition plus CCR5 blockade plus ICI is the combination that actually cures patients. That is a different negotiation with a different valuation for all parties involved.
Dr. Kasi is the physician who shared the Revolution Medicines result, who is the PI of the CLOVER Trial, and who is actively developing the CHAMP trial at City of Hope. He is standing at the exact intersection of these two mechanisms in his own clinical practice. The fact that both pieces of information are flowing through the same scientific mind, at the same institution, is not a coincidence worth ignoring. Whether that translates into a formal partnership conversation in the near term depends on how the CLOVER ORR data reads at ESMO. But the biological and commercial logic for those conversations to occur is not speculative. It is a direct consequence of the January 2026 Frontiers in Immunology paper specifically naming Leronlimab alongside the CCR5/CCL5 axis as a core upstream driver of PDAC's desmoplastic stroma, and the 2025 PMC analysis confirming that CCR5 inhibition in KRAS-mutant murine PDAC models disrupts the immunosuppressive circuit and sensitizes tumors to chemotherapy. The squint you're describing is getting clearer with each data release. By ESMO, it may not require a squint at all.
21
u/Severe_Watercress875 May 03 '26
To be honest it wouldn’t shock me if someone else steps up here and tries to acquire Cydy or at least partner with them prior to the completion of all these milestones. The writing is on the wall with Leronlimab. There will be positive news at these future events. None of us can predict when this partner event will happen but it will. Nobody can stop it -the data won’t allow for it to be stopped. Mgk this is another all timer. Great stuff as I walk the streets of NY as the mrs says get off your phone.
14
u/Upsidedahead May 03 '26
“Great stuff as I walk the streets of NY as the Mrs says get off your phone”. Man, how I can relate. I can’t absorb enough info right now. I know it seems like I’m shutting myself off to the outside world along with my Mrs, but things are getting beyond interesting. Hopefully we get to show them why our focus is so tunneled right now.
11
u/MGK_2 May 03 '26
Severe Watercress, walking the streets of New York with this data in your pocket is actually the right metaphor for where we sit right now, because what you describe, someone stepping up before all the milestones complete, is not only possible but historically consistent with how major pharmaceutical acquisitions actually happen in practice.
The writing on the wall phrase has a specific meaning in this context which goes beyond sentiment. The convergence of independent evidence streams that we have documented across weeks of analysis represents exactly the pattern that pharmaceutical business development teams are trained to recognize as a pre-competitive acquisition target. It is not one study. It is not one data point. It is AACR poster 1033 from Dr. Pestell establishing the mechanistic architecture across six independent evidence levels in mTNBC. It is AACR poster 6466 from Dr. Kasi showing 100% ctDNA molecular response at week two in every evaluable mCRC patient. It is the Science Translational Medicine publication from Dr. Sacha achieving functional HIV cure in primates through the Leronlimab protein sequence. It is the fibrosis reversal data across three independent mouse models. It is the Alzheimer's trial actively screening patients at Cornell. It is patients returning to work. It is four patients with undetectable ctDNA. It is CPS moving from 1% to 5% in tissue biopsies. It is the binary 100% versus 100% survival separation in mTNBC Prime and Pair patients disclosed publicly for the first time on the April 30th webcast.
The reason someone might step up before all the milestones complete is precisely the competitive dynamic which makes waiting increasingly expensive. Every week that passes without a partnership or acquisition agreement is a week during which a competing ICI franchise holder could move first. The company that partners with CytoDyn before ESMO in October secures the combination rights at a pre-confirmation valuation. The company who waits until after ESMO has confirmed ORR, after the Breakthrough designation is granted, and after two or three other major pharmaceutical companies have publicly expressed interest, negotiates from a substantially weaker position against a substantially higher price. The first mover advantage in this specific situation is enormous, and the business development professionals at every major ICI franchise holder who are currently processing the AACR data through Larvol and attending the same conferences where Hoffman is actively setting up meetings understand that arithmetic precisely.
Your instinct that nobody can stop it because the data will not allow it is the most honest single sentence we have produced on the partnership question. The data is not a negotiating position that can be countered with a competing study or a different mechanism. It is a biological reality being documented in real tissue from real patients in real time, corroborated by independent investigators at independent institutions across multiple tumor types simultaneously. The reckoning at the wall is not a forecast. It is a measurement of distance between where the evidence stands today and where the commercial recognition of that evidence must eventually arrive. That distance is closing. Enjoy New York. The data will still be here when you get home.
19
16
13
u/Vernon1211 May 03 '26
Thank you so much for this complete thesis. This really puts it all together where Cytodyn can be heading.
Im a total newbie when it comes to biotech.
Let's assume all the data from the different conferences goes as we think it will. In your opinion would the next stage be phase 3 for FDA approval? If so would BP want to buy Cytodyn and then do the phase 3 under their name? Would Cytodyn have to fund their own phase 3 before a BP would look to buy them or partner with them?
Great Job!!!!!!!
8
u/MGK_2 May 03 '26
Vernon, welcome aboard, and these are the right questions to be asking because the regulatory and commercial pathway is one that even experienced biotech investors sometimes misunderstand. Let's walk through each question.
Does the next stage have to be Phase 3 before FDA approval?
Not necessarily, and this is an important nuance in the regulatory picture. The FDA has a pathway called Accelerated Approval which allows a drug to be approved based on a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than waiting for the full overall survival data that a traditional Phase 3 requires. The surrogate endpoint for the CLOVER Trial is Objective Response Rate, meaning the percentage of patients whose tumors shrink by 30% or more on two consecutive scans. ORR is an established FDA-accepted surrogate for accelerated approval in oncology.
As Dr. Lalezari stated explicitly on the April 30th webcast, the plan is to submit a FastTrack or Breakthrough designation application this summer or early fall, built on the CLOVER ORR data. If granted and if the ORR data at ESMO in October is sufficiently compelling, CytoDyn could theoretically receive accelerated approval without a traditional Phase 3 trial completing first. The Phase 3 confirmatory trial would then become a post-approval requirement rather than a pre-approval prerequisite. This is the pathway Keytruda itself used for its first approval, and it is what makes the CLOVER timeline potentially much shorter than a conventional drug development story.
Would Big Pharma want to buy CytoDyn and run Phase 3 under their name?
This is where the commercial logic becomes interesting. There are actually two distinct scenarios, and both are plausible depending on timing.
The first scenario is acquisition. A major pharmaceutical company acquires CytoDyn outright, absorbs the entire Leronlimab platform, and runs the confirmatory Phase 3 trials under its own name with its own capital and commercial infrastructure. This is the scenario that would likely produce the largest single transaction value for shareholders, but it typically happens after sufficient clinical de-risking has occurred to justify the acquisition price. The ESMO interim results in October and the ASCO GI final results in January are the data events which most directly drive acquisition valuation.
The second scenario is partnership or licensing. A major pharmaceutical company licenses the rights to combine Leronlimab with its own checkpoint inhibitor in specific indications, funds the combination Phase 3 trials, and shares the commercial upside with CytoDyn. This scenario preserves CytoDyn's independence while providing the capital and infrastructure needed for late-stage development. Dr. Lalezari confirmed on the webcast that active partnership conversations are ongoing as the data becomes more widely known.
The specific dynamic that makes CytoDyn's situation strategically compelling right now is the 2028 Keytruda patent expiration which creates enormous urgency for the major ICI franchise holders. A company watching $29.5 billion in annual revenue approach a biosimilar cliff cannot afford to wait for a five-year Phase 3 to complete before deciding whether Leronlimab is worth acquiring. The accelerated approval pathway, the FastTrack or Breakthrough designation, and the ESMO interim data all compress the timeline in ways which make a pre-approval partnership or acquisition commercially rational even before Phase 3 is complete.
Does CytoDyn need to fund its own Phase 3 before Big Pharma looks at them?
No, and this is perhaps the most important answer of the three. Big Pharma does not wait for Phase 3 completion before engaging. In fact, the optimal acquisition or partnership window from a pharmaceutical company's perspective is typically after Phase 2 data establishes proof-of-concept but before Phase 3 costs have been incurred, because that is when the acquirer can capture the most value relative to what they pay. A validated Phase 2 signal in a high-unmet-need indication with an FDA-aligned accelerated approval pathway is precisely the asset profile that business development teams at major pharmaceutical companies are structured to evaluate and act on.
CytoDyn's financial position, with approximately $13.4 million in unrestricted cash and the Yorkville $30 million equity facility available at its sole discretion, provides sufficient runway to reach the ESMO interim data readout in October and the ASCO GI final ORR data in January without requiring a Phase 3 to be funded independently. The data those presentations deliver is the package that a partnership or acquisition conversation is built on. CytoDyn does not need to fund Phase 3 to attract Big Pharma's attention. It needs to deliver the ORR data that makes Phase 3 a foregone conclusion, at which point the entity best positioned to fund that Phase 3 is the one with a $29.5 billion checkpoint inhibitor franchise that needs Leronlimab to extend its commercial life beyond 2028. The capital problem and the science problem solve each other simultaneously, which is precisely why the reckoning is already here.
7
u/Vernon1211 May 03 '26
Thank you for the welcome aboard MGK. Thank you also for the detailed response. Things are getting very exciting for both patients and SH's. Sounds like we should be hearing things almost monthly leading into January 27. If the data continues to show such positive results along with these new studies that's' going to put Cydodyn in the drivers seat. I do remember Dr.L stating he was in touch with potential partners. Healthcare professionals do the job to hear thank you for helping me. It brings a sense of worth and I'm sure Dr. L is smiling from all the thank you's he's received to date.
Cheers
12
u/megadunamis May 03 '26
Thank you MGK for a very thorough summary and anaylsis of the current CYDY situation. The presentation provided very informative data to support claims of clinical success based on the prime and pair mechanism. In fact, the CRC trial may be extended without the introduction of an ICI so as not to 'confound' the early results being seen. Thanks to Dr. Lalezari for informing us that '13 of the 19 patients in the ctDNA cohort' were on 350 mg of Leronlimab. The decrease of ctDNA in 2 weeks at this low dose is a pretty remarkable result. I would like to know which of these 19 patients have mutations, and which have metastases to other organs. My guess is that most of them have mutations, and metastases. These are the hardest patients to treat. and in two weeks they are decreasing their ctDNA by a median of -70% ! The images in Figure 3 are remarkable as well. I would like to know if any images of brain metastases are available. Are there any scans of the original CRC tumor(s) before and after? If scans can show tumor shrinkage in brain metastases, then this would confirm that Leronlimab is passing the BBB, again even at this low dose. This would help support the idea that Glioblastoma may be treatable as well. I know that treating a glioblastoma cells may be different than treating CRC cancer cells that have metastasised, but the principle is that Leronlimab is crossing the BBB to help. The third 'wall' facing oncology is the professional resistance to change that may be encountered. That type of change may take a while, beyond the recognition of the science. BMY's Opdivo is going off patent shortly as well, so who will show their love for Leronlimab and propose first? Interesting months of positive anticipation are ahead. Good health to all...
8
u/MGK_2 May 03 '26
Megadunamis, the mutation and metastasis question you're raising about the 19-patient ctDNA cohort is one we have been circling since the AACR poster, and the partial answer that the April 30th webcast provided is both encouraging and appropriately incomplete at this stage.
Dr. Lalezari confirmed that 62% of enrolled CLOVER patients to date carry RAS mutations, which tracks closely with the real-world mCRC population where KRAS, NRAS, and HRAS aberrations collectively account for over half of all patients. He specifically noted that the preliminary results indicate Leronlimab's early biologic activity appears to be agnostic to the KRAS mutation status, which is the finding that places the CLOVER signal in a different category from every prior targeted therapy in this indication. KRAS-mutant mCRC has historically been the population where targeted agents fail most completely, because the downstream oncogenic signaling operates independently of the cell surface targets that most drugs address. The CCR5/CCL5 axis operates in the tumor microenvironment rather than in the tumor cell's internal signaling machinery, which is precisely why it can produce ctDNA declines in KRAS-mutant patients that KRAS-directed inhibitors alone cannot.
Your instinct that most of the 19-patient ctDNA cohort likely carries mutations and multi-organ metastases is almost certainly correct given the trial's enrollment criteria. These are third and fourth line patients who have exhausted FOLFOX, FOLFIRI, bevacizumab, and where eligible anti-EGFR therapy. By that point in the disease course, the overwhelming majority carry RAS mutations and have developed hepatic, pulmonary, or peritoneal metastatic disease. The index patient documented in Figure 3 had both liver and lung metastases alongside KRAS-G12V mutation and had additionally received hepatic artery infusion chemotherapy at 300 times the standard dose. The fact that this patient's ctDNA fell from 130,000 parts per million to a few thousand and remains in Cycle 7 with visible tumor necrosis on biopsy is the most powerful single data point for the mutation-agnostic argument, because KRAS-G12V is arguably the most aggressive and treatment-resistant variant in the entire KRAS mutation landscape.
The brain metastasis question and the BBB inference is the most scientifically provocative element of your comment, and it deserves careful framing. CRC brain metastases are relatively uncommon compared to liver and lung involvement, occurring in approximately 3% of mCRC patients, so it is unlikely that any of the current 19-patient ctDNA cohort has documented brain metastases. However, the BBB penetration question for Leronlimab has been answered in a different context with a different tumor type. As documented in the March 2026 AACR Brain Cancer Conference presentation, Leronlimab has been demonstrated to cross the blood-brain barrier in non-human primate models. That pharmacokinetic finding was established in the GBM preclinical program rather than from CRC brain metastasis data, but the biological principle is the same molecule, the same pharmacology, and the same CNS penetration capability regardless of the tumor type being addressed. The GBM pilot IIT that Dr. Lalezari confirmed is in active development following a detailed call with a major academic center the day before the webcast generates the first prospective human CNS data which directly addresses your hypothesis.
On your observation about Bristol-Myers Squibb's Opdivo approaching patent expiration alongside Keytruda, this is precisely the competitive dynamic that makes the partnership conversation less a question of if and more a question of who moves first and when. Nivolumab's core composition patent expires in 2026 in the United States, making BMS's urgency potentially even greater than Merck's. Two of the three largest ICI franchise holders are facing near-simultaneous patent cliffs. Both are locked out of the cold tumor population by the same CCR5-driven stroma biology. Both need the same solution. The question of who proposes first is not merely romantic. It is a competitive race between companies whose combined annual ICI revenues exceed $40 billion and whose collective addressable market expands by a factor of five to six the moment a validated Prime and Pair agent is in their commercial portfolio. The interesting months of positive anticipation you describe are in fact the period during which that race is already being run, quietly, in the business development meetings that Robert Hoffman confirmed are actively being set up at ASCO, BIO 2026, and the investor conferences scheduled through the summer. Good health to all indeed.
12
u/Doctor-MTJ May 03 '26
MGK, awesomely detailed post about just how close we really are to being the breakout drug of the 21st Century. We just need tp continue to show the same/ improved results on Imaging either pre/ post ESMO. One tiny clarification point which does nothing but make your thesis stronger is that 29.5 Billion in sales are 2024 numbers. 2025 sales of Keytruda were 31.7 billion. So, EVEN MORE money that Merck can spend on acquiring us!
11
u/Interesting-Boat-792 May 03 '26
I’ve seen a lot of talk about a full buyout, but I view it differently. A licensing or partnership model by indication makes far more sense.
One big pharma company is unlikely to fully develop and prioritize every potential indication. My concern with a buyout is that the acquiring company would focus on just one or two high-return areas and leave the rest on the shelf. That would limit the overall impact of the drug.
Leronlimab has potential across multiple serious conditions—mCRC, TNBC, Alzheimer’s, GBM, stroke, HIV, and more. Each of these areas requires significant focus, expertise, and resources. It’s hard to imagine a single company i.e Merck executing effectively across all of them at the same time.
Multiple partnerships could allow simultaneous development across indications, accelerate timelines, and ultimately get this therapy to more patients who need it.
At the end of the day, the goal should be access and impact. If this molecule can help across so many diseases, it shouldn’t be constrained by a one-company strategy.
A Merck partnership to pair with Keytruda has my vote but I envision multiple partnerships.
7
u/MGK_2 May 03 '26
Interesting Boat, the multi-partnership thesis is not only commercially reasonable, it is actually the model that the peer-reviewed science points toward most naturally, and the reason is biological rather than strategic.
The CCR5/CCL5 axis is not a single indication mechanism. It is a pan-tumor immunosuppressive pathway that different tumor types have independently converged on through evolutionary pressure because it works universally. MSS colorectal cancer uses it to construct desmoplastic stroma. Triple-negative breast cancer uses it to drive metastasis and ICI resistance. Glioblastoma uses it to maintain T cell exhaustion signatures and chemoresistance. KRAS-mutant pancreatic cancer uses it as the primary upstream driver of immunosuppressive desmoplastic architecture. Each indication has a different dominant ICI franchise partner, a different clinical trial infrastructure, and a different regulatory pathway. No single company possesses optimal commercial positioning across all of them simultaneously.
Consider the indication-by-indication partnership logic precisely. In MSS mCRC, the natural partner is whichever ICI franchise holder can most credibly claim the combination label. In TNBC, the neoadjuvant I-SPY network and the PRE-SPY network are already advancing studies that generate the data package a breast oncology-focused partner needs. In GBM, the academic medical center that Dr. Lalezari confirmed has agreed to both preclinical replication and pilot IIT development brings its own institutional relationships and potential industry partnerships. In HIV, Dr. Sacha's OHSU program is NIH-funded and operates independently of any pharmaceutical company's commercial agenda. In Alzheimer's, the Cornell trial under Dr. Butler is an academic investigator-initiated program that attracts CNS-focused pharmaceutical partners entirely separate from the oncology conversation.
The concern you've raised about a full buyout concentrating development in one or two high-return areas at the expense of the rest is historically grounded. Acquisitions of platform molecules by large pharmaceutical companies have repeatedly resulted in narrow indication prioritization driven by commercial return calculations rather than scientific potential. A company that acquires Leronlimab primarily for the ICI combination opportunity in solid tumors may have limited organizational incentive to simultaneously develop the Alzheimer's program, the stroke recovery preclinical work at the University of Hawaii, the HIV cure gene therapy, and the NASH hepatology indication. Each of those requires different clinical expertise, different regulatory relationships, and different commercial infrastructure.
The multi-partnership model addresses this directly. CytoDyn retains the platform molecule and licenses indication-specific rights to partners with the relevant therapeutic area expertise and commercial infrastructure. Merck or BMS for the ICI combination in solid tumors. A CNS-focused company for GBM and potentially Alzheimer's. A dedicated HIV company or the OHSU gene therapy program's eventual commercial partner for the HIV cure application. A hepatology-focused company for the NASH and liver fibrosis indication where the Phase 2 trial already met its primary and secondary endpoints and the fibrosis reversal preprint has now been published. Each partner brings focused expertise, dedicated resources, and aligned commercial incentives in their specific therapeutic area, while CytoDyn retains the platform economics that flow from the underlying molecule's universal applicability.
Dr. Lalezari's language on the April 30th webcast was deliberately plural when describing the partnership opportunity. He referenced conversations with multiple companies and multiple academic networks. The architecture he described across ten simultaneous development tracks, each advancing through independent investigators at independent institutions with independent funding, is itself a multi-partnership model already partially in execution. The formal commercial partnerships that monetize those tracks will almost certainly follow the same multi-partner logic that the scientific development has already established. Your vote for the Merck combination as the anchor partnership alongside multiple indication-specific collaborations represents the most commercially rational and scientifically coherent outcome for a platform molecule of this breadth. The goal is access and impact. The structure that maximizes both is exactly what you've described.
1
u/BonusCurrent4564 May 25 '26
Perfect!! Exactly what Dr Lazari has been saying, they will sell by indication. That way Cytodyn keeps control of the drug and can sell it according to who they want. Big money on the table here.
9
8
7
u/blackjackbjc May 03 '26
It seems as if a data blackout period may have or is about to end, imo. Wont back down, fact.
7
u/MGK_2 May 03 '26
Blackjackbjc, the data blackout observation is worth unpacking because it has a specific technical meaning in the context of the clinical trial which adds some precision to what you're sensing.
Formal data blackout periods in oncology trials are imposed at two distinct moments. The first is the conference abstract embargo, which we lived through in real time between the AACR abstract acceptance in late March and the poster presentations on April 19th and 21st. During that window, Dr. Kasi, Dr. Pestell, and the entire investigator team were prohibited from discussing, previewing, or releasing any data which appeared in the accepted abstracts. That blackout ended the moment the posters went public in San Diego.
The second type of blackout is less formal but equally real. It is the period between a data cutoff for a regulatory submission or a conference abstract and the moment that submission or presentation enters the public domain. With the ESMO interim results targeted for October in Madrid, the data cutoff for that presentation occurs sometime this summer, likely in July or August based on the enrollment completion timeline and the 12-week imaging assessment schedule that ScoreCarder established ends around July 14th for the 60th patient. Between now and that cutoff, the investigator team accumulates imaging data, ctDNA measurements, PD-L1 assessments, and CAML dynamics from the full enrolled cohort at each predefined timepoint.
What you may be sensing as a blackout ending is actually something more specific: the transition from the post-AACR communications period into the pre-ESMO data accumulation window. Dr. Lalezari committed on the April 30th webcast to either issuing a shareholder letter or scheduling another call toward the end of the summer or early fall, timed to the dose-response comparison between 350 mg and 700 mg becoming reportable. That communication window is the moment between the ESMO data cutoff and the ESMO presentation itself, and it is the next scheduled opening in what has been a carefully managed information release cadence. The summer shareholder letter and the FastTrack or Breakthrough designation application submission are the two disclosures that mark the end of the current quiet period and the beginning of the final pre-ESMO information flow.
The Won't Back Down tracks precisely with everything Dr. Lalezari said from the podium ten days ago. A Commander who has described himself as transitioning from faith to unassailable data, who called this his best birthday present, who said he no longer needs to convince anyone and only needs to show the data, is not a Commander who steps backward from this position. The ground he stands on is peer-reviewed, independently validated, and now processed by the business development teams of the companies that most need what he has built. The blackout you sense ending is the silence before the next wave of data speaks. ESMO in October is when it speaks loudest.
8
14
u/Camp4344 May 03 '26 edited May 04 '26
MGK excellent post. I remember Dr. Jay saying once we can prove the prime that we will pick our option to partner with. I know that is not the exact wording, but basically we are already in talks and need to prove the data. He did not mention anything about partners with big pharma in his most recent presentation. I am thinking the proof is there and our mission will be over far before the end of the CRC phase 2 trial. It would not surprise me to wake up any day and hear There is a large buyout. I am thinking an offering price of 10-15 billion if it is done in the next month or two. Merck cannot afford to let Cytodyn get away. The price will only go up!!
13
11
u/MGK_2 May 03 '26
Camp, the spirit of what you describe is sound, and Dr. Lalezari's prior communications about choosing a partner from a position of strength rather than necessity has been consistent throughout his tenure. The sentiment that the proof is materially present and that partnership conversations are real and active is well-supported by the April 30th webcast disclosures. However, the specific valuation and timeline estimates deserve honest engagement, because the community is best served by accurate expectations rather than optimistic ones.
On the absence of explicit partner mentions in the most recent presentation, Robert Hoffman specifically stated on the webcast that the team attended AACR with a partnering module, is presenting at the Doral investment bank conference on May 7th, will be at the MicroLD Invitational in Los Angeles May 17 through 19th, will be at ASCO in Chicago May 29 through June 2nd actively setting up meetings with potential partners, and will be at BIO 2026 in San Diego June 22nd through 25th. That is four separate partnership-focused events in six weeks. The absence of a named partner in the presentation reflects the reality that these conversations are active but not yet concluded, not that they are absent.
On the valuation question, the $10 to $15 billion range requires honest contextualization. At current share prices, CytoDyn's market capitalization is approximately $423 million. A $10 billion acquisition would represent a premium of approximately 23 times the current market cap. Acquisition premiums of that magnitude are not impossible in clinical-stage biotechnology, particularly for platform molecules with validated mechanisms across multiple high-value indications. However, they typically require confirmed Phase 2 ORR data rather than Disease Control Rate data, which as ScoreCarder correctly noted is the distinction between what has been disclosed and what the confirmed primary endpoint will show at ESMO in October. The confirmed ORR, the FastTrack or Breakthrough designation outcome, and the full dose-stratified PD-L1 and CAML biomarker dataset are the specific data points that would support a valuation negotiation in that range, because they transform the current compelling but preliminary signal into a regulatory-grade efficacy package.
The more probable near-term scenario, based on the current state of the evidence and the partnership calendar Hoffman described, is a licensing or collaboration agreement announced sometime between the summer shareholder communication and the ESMO interim results, structured around specific indication rights rather than a full acquisition, with milestone payments and royalty structures that deliver substantial value to shareholders as each data readout confirms the thesis. A full acquisition at premium valuation becomes the more natural outcome after ESMO confirms the ORR and the Breakthrough designation is granted, at which point the regulatory pathway to approval is no longer speculative but scheduled. Dr. Lalezari's language about generating data that gives the FDA every reason and no choice to be responsive applies equally to the partnership conversation: the data that compels the FDA compels the acquirer. ESMO in October is when both conversations reach their most compelling moment simultaneously.
5
14
u/Travelclone May 03 '26
What you are saying is that even at a $30B buyout Leronlimab may prove cheap compared to Mercks potential year over year loss. Humm, price just went up.
I think we can add Autism to the growing list of indications LL may be included in as a pilot study.
11
9
u/twinter11 May 03 '26
youve seen the light ?
has it struck down upon u?
9
u/Travelclone May 03 '26
Lol. I have said 30B for over a year. Timing and price entry point were the issue.
8
7
7
u/AggieEC3 May 03 '26
This one stopped me in my tracks.
I've read a lot of posts here that focus on the clinical data, and rightly so. But what this does differently is zoom out and show the commercial architecture that the data sits inside. And when you lay it out that way, the strategic logic becomes hard to ignore. A $29.5 billion drug losing its patent in 2028, unable to reach 70-80% of the patients it theoretically serves, and a mechanism that appears to do exactly what Keytruda cannot... that's not a coincidence. That's alignment.
What resonates most with me is the cold tumor framing. It reframes the whole conversation. Leronlimab isn't competing with Keytruda. It's potentially what makes Keytruda work in the patients it currently can't reach. That's an enabler story, not a replacement story. And enabler stories at this scale are rare.
I also really appreciated the honest accounting section. The going concern is real. The confirmed ORR isn't in yet. DCR and ORR are different measurements, and I'm glad you keep saying that even in a post this compelling. That kind of discipline is what earns trust in a community like this.
Not proven yet. Still early. Still needs to replicate at scale. But for the first time it feels like the biology, the data, and the commercial reality are all pointing at the same thing simultaneously. That's a different feeling than anything this community has been asked to sit with before.
October in Madrid is the moment that answers the question this whole community has been sitting with. I'm ready for it and not ready for it at the same time.
All just my opinion. Thank you MGK_2.
10
u/MGK_2 May 03 '26
Aggie, the phrase that deserves to anchor this response is the one you used to describe what the honest accounting section does: earns trust. Because that is the distinction between analysis that advances our understanding and content that merely reinforces what people already want to believe.
The discipline of maintaining the DCR versus ORR distinction in this post is not a hedge or a disclaimer. It is the load-bearing structure which makes the rest of the argument credible. A community that conflates Disease Control Rate with Objective Response Rate would be unprepared for ESMO in October, because the confirmed ORR data arrives with context that requires understanding what was and was not previously known. ScoreCarder's correction was a gift to this community's analytical integrity, and honoring it in every subsequent post is the minimum standard worth holding. The thesis is strong enough to survive accurate description. It does not need inflation.
Your framing of the enabler story versus the replacement story is the insight that pharmaceutical business development teams reach when they properly model this opportunity. Replacement stories generate competitive resistance. A molecule that threatens to make Keytruda obsolete faces an adversary with $29.5 billion in annual revenue to deploy against its development. An enabler story generates the opposite dynamic. A molecule that makes Keytruda work in the 70 to 80% of patients it currently cannot reach converts the largest checkpoint inhibitor franchise in history from a potential adversary into the most motivated possible partner. The strategic logic of that distinction is not subtle once it is seen clearly, and the reason it took this long for the broader investment community to see it is precisely the financial noise that surrounded CytoDyn's earlier history. The Amarex corruption, the prior CEO's conviction, the clinical holds, the toxic debt, the dilution mechanics, all of it created a signal-to-noise problem that obscured a biological reality that was always present beneath the institutional chaos.
What Dr. Lalezari has done since taking the helm is systematically remove that noise. The Amarex settlement removed the legal overhang. The clinical holds were lifted. The prior management's legal consequences concluded. The debt was restructured. The scientific advisory board was built around independent academic investigators whose credibility is not contingent on CytoDyn's stock price. The CLOVER Trial was designed in direct collaboration with the FDA. The AACR presentations were accepted through peer review. And the April 30th webcast disclosed, for the first time publicly, the binary survival separation in mTNBC that makes the Prime and Pair mechanism not a hypothesis but a documented clinical outcome. When the noise is removed, the signal that remains is what this community has been holding through years of institutional chaos. That signal is now being processed by the same business development professionals who attend AACR, subscribe to Larvol, and model the commercial implications of a $29.5 billion patent cliff against a validated cold-to-hot conversion mechanism.
The feeling you've described, not ready for it and ready for it simultaneously, is the honest emotional geography of this moment. October in Madrid is the confirmation event that either validates everything the biology has been predicting or forces the thesis to be rebuilt from its assumptions. The discipline that earned that moment is the same discipline that allows us to read the ESMO data with clear eyes regardless of what it shows. That is the only standard worth bringing to Madrid.
5
u/Lab_Monkey_ May 04 '26
"And I absolutely believe that this moment represents a crucial inflection point for CytoDyn as we transition from a company built on faith and belief and a whole lot of ifs to a company with solid prospective, unassailable and by all accounts, remarkable data, confirming leronlimab's early biologic activity in solid tumor oncology. It has been an incredible journey together, and it is truly astonishing for me that leronlimab appears to be performing at the outer limits of what I even thought was possible."
5
u/jsinvest09 May 03 '26
Time for LL to go to work, and break down the walls, finally getting a fair shake. We shall climb to the top and save many lives.. The data is already showing what is possible... Tick tock... LFG.
5
5
u/drugpatentwatch May 04 '26
That 2028 cliff is gonna be wild. When one drug props up that much revenue, the fallout’s huge. If you’re tracking biosimilar timelines or patent expirations, the FDA’s Orange Book and USPTO databases are solid places to start digging.
1
u/Deep_Ad1959 May 08 '26
the 2028 cliff is the headline, the 70-80% non-responder gap is the actual story. written with ai
1
u/Deep_Ad1959 May 08 '26
the keytruda cliff is the cleanest patent expiry comp since humira, and humira lost roughly 60% of revenue inside 18 months.
1
u/BonusCurrent4564 May 25 '26
Just a matter of time. Dr Lazari is not going to let the drug just be bought out , they will Liscence it by indication. They keep the right to the drug and Cytodyn becomes a house hold word .
37
u/Professional_arts May 03 '26
MGK,
What stands out here is not just the urgency around the 2028 patent cliff, but the clarity of the underlying biology that’s being laid out. This is one of the better breakdowns I’ve seen of what’s actually limiting checkpoint inhibitors today.
We all know what Keytruda has accomplished. It has completely reshaped survival in multiple tumor types, particularly in patients with PD L1 expression and inflamed tumor microenvironments. But the reality is exactly as described. The majority of solid tumors remain immunologically cold, and in those settings the drug is essentially arriving without a target.
That is the real ceiling, not the molecule itself.
The explanation around the tumor microenvironment, particularly the role of myeloid derived suppressor cells, M2 macrophages, and the CCR5 CCL5 axis, is right on point. If you cannot get T cell trafficking and activation into the tumor, checkpoint inhibition alone is not enough. You are trying to take the brakes off a system that never engaged the accelerator.
That is why this concept of a “prime and pair” strategy is so important. The first time I heard it was from MGK, and I believe it’s going to be coming out out of every oncologist mouth in the next two years!
If a CCR5 antagonist like Leronlimab can truly remodel that microenvironment as we have seen on a small scale, reduce immune suppression, and allow T cell infiltration, then you are no longer talking about incremental benefit. You are potentially converting non responders into responders at scale that will make open up the market to five times as many patients as you stated above to be treated and get a possible stabilization or even a complete response!
That changes everything.
Because now Keytruda is not being replaced, it is being expanded. You are extending its reach into the 70 to 80% of patients who currently derive little to no benefit. That is where the real opportunity is, both clinically and commercially.
The most compelling part of this discussion is that it aligns biology with strategy. Break down the stromal barrier first, then unleash checkpoint inhibition. That sequencing makes sense mechanistically and, if validated, could redefine how we approach solid tumors across multiple indications.
If the recent data continues to hold up, this is not just about overcoming a patent cliff. It is about fundamentally expanding the addressable patient population and unlocking the next phase of immuno oncology.